SI2739153T1 - Zdravljenje raka dojke - Google Patents

Zdravljenje raka dojke

Info

Publication number: SI2739153T1
Authority: SI; Slovenia
Prior art keywords: treatment; breast cancer; breast; cancer
Prior art date: 2011-07-29

Application number

SI201231453T

Other languages

English (en)

Inventor

Andrew A. Protter

Jennifer Richer

Dawn Cochrane

Original Assignee

Medivation Prostate Therapeutics Llc

The Regents Of The University Of Colorado, A Body Corporate

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-07-29

Filing date

2012-07-27

Publication date

2018-12-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2739153(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-07-27 Application filed by Medivation Prostate Therapeutics Llc, The Regents Of The University Of Colorado, A Body Corporate filed Critical Medivation Prostate Therapeutics Llc

2018-12-31 Publication of SI2739153T1 publication Critical patent/SI2739153T1/sl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SI201231453T 2011-07-29 2012-07-27 Zdravljenje raka dojke SI2739153T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161513361P	2011-07-29	2011-07-29
PCT/US2012/048471 WO2013066440A1 (en)	2011-07-29	2012-07-27	Treatment of breast cancer
EP12846720.6A EP2739153B1 (en)	2011-07-29	2012-07-27	Treatment of breast cancer

Publications (1)

Publication Number	Publication Date
SI2739153T1 true SI2739153T1 (sl)	2018-12-31

Family

ID=48192564

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI201231453T SI2739153T1 (sl)	2011-07-29	2012-07-27	Zdravljenje raka dojke

Country Status (18)

Country	Link
US (4)	US9517229B2 (sl)
EP (4)	EP3610731A1 (sl)
JP (2)	JP6158180B2 (sl)
KR (1)	KR101923250B1 (sl)
CN (1)	CN103997894B (sl)
BR (1)	BR112014002200A2 (sl)
CA (1)	CA2843417C (sl)
CY (1)	CY1121038T1 (sl)
DK (1)	DK2739153T3 (sl)
EA (1)	EA028452B1 (sl)
ES (1)	ES2696074T3 (sl)
HU (1)	HUE040524T2 (sl)
MX (1)	MX359664B (sl)
PH (1)	PH12014500248B1 (sl)
PL (1)	PL2739153T3 (sl)
PT (1)	PT2739153T (sl)
SI (1)	SI2739153T1 (sl)
WO (1)	WO2013066440A1 (sl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103997894B (zh) *	2011-07-29	2016-08-24	麦迪韦逊前列腺治疗股份有限公司	乳癌的治疗
GB201216017D0 (en)	2012-09-07	2012-10-24	Cancer Rec Tech Ltd	Inhibitor compounds
PT3305285T (pt)	2012-09-26	2020-11-24	Aragon Pharmaceuticals Inc	Antiandrogénios para o tratamento de cancro da próstata resistente à castração não metastático
JOP20200097A1 (ar)	2013-01-15	2017-06-16	Aragon Pharmaceuticals Inc	معدل مستقبل أندروجين واستخداماته
BR112015026257B1 (pt) *	2013-04-17	2022-12-20	Signal Pharmaceuticals, Llc	Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
JP6568093B2 (ja) *	2013-11-07	2019-08-28	デシフェラファーマシューティカルズ，エルエルシー	ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
JP6945587B2 (ja) *	2013-11-07	2021-10-06	デシフェラファーマシューティカルズ，エルエルシー	ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
WO2015184145A1 (en) *	2014-05-28	2015-12-03	Eisai R&D Management Co., Ltd.	Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
CA2970469A1 (en)	2014-12-12	2016-06-16	Amy Christian Peterson	Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
WO2016141167A1 (en)	2015-03-03	2016-09-09	Cureport, Inc.	Combination liposomal pharmaceutical formulations
WO2016141161A1 (en)	2015-03-03	2016-09-09	Cureport, Inc.	Dual loaded liposomal pharmaceutical formulations
CN104857517B (zh) *	2015-05-14	2018-04-27	南京海纳医药科技股份有限公司	一种恩杂鲁胺软胶囊及其制备方法
US9963433B2 (en) *	2016-01-29	2018-05-08	Wayne State University	Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
EP3641772B1 (en)	2017-06-22	2023-08-02	Celgene Corporation	Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
EP4438126A3 (en)	2017-10-16	2025-01-01	Aragon Pharmaceuticals, Inc.	Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN107987055A (zh) *	2017-12-19	2018-05-04	刘秀云	硫代咪唑二酮类雄激素受体拮抗剂及其用途
JP7523351B2 (ja)	2018-01-31	2024-07-26	デシフェラ・ファーマシューティカルズ，エルエルシー	肥満細胞症の治療のための併用療法
JP2021512105A (ja)	2018-01-31	2021-05-13	デシフェラ・ファーマシューティカルズ，エルエルシー	消化管間質腫瘍の治療のための併用療法
US11034669B2 (en)	2018-11-30	2021-06-15	Nuvation Bio Inc.	Pyrrole and pyrazole compounds and methods of use thereof
AU2019387367A1 (en)	2018-11-30	2021-06-10	Nuvation Bio Inc.	Diarylhydantoin compounds and methods of use thereof
NZ784949A (en)	2019-08-12	2025-09-26	Deciphera Pharmaceuticals Llc	Ripretinib for treating gastrointestinal stromal tumors
TWI878335B (zh)	2019-08-12	2025-04-01	美商迪賽孚爾製藥有限公司	治療胃腸道基質瘤方法
AU2020419197B2 (en)	2019-12-30	2023-08-31	Deciphera Pharmaceuticals, Llc	Amorphous kinase inhibitor formulations and methods of use thereof
NZ789199A (en)	2019-12-30	2025-07-25	Deciphera Pharmaceuticals Llc	Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
JP2023536636A (ja) *	2020-08-03	2023-08-28	オンコサイト・コーポレイション	腫瘍の分類及び応答性の予測
US11779572B1 (en)	2022-09-02	2023-10-10	Deciphera Pharmaceuticals, Llc	Methods of treating gastrointestinal stromal tumors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4559157A (en)	1983-04-21	1985-12-17	Creative Products Resource Associates, Ltd.	Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr)	1983-08-30	1985-04-24	Oreal	Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en)	1987-06-23	1989-04-11	Neutrogena Corporation	Skin protective composition
US4992478A (en)	1988-04-04	1991-02-12	Warner-Lambert Company	Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en)	1988-09-12	1990-07-03	University Of New York	Treatment of damaged bone marrow and dosage units therefor
RS52274B2 (sr) *	2005-05-13	2018-05-31	Univ California	Jedinjenje diarilhidantoina
US7709517B2 (en) *	2005-05-13	2010-05-04	The Regents Of The University Of California	Diarylhydantoin compounds
EP1954708A4 (en)	2005-11-23	2009-05-13	Univ Utah Res Found	Methods and compositions involving intrinsic genes
PL3412290T3 (pl) *	2006-03-27	2021-09-06	The Regents Of The University Of California	Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym
CA2648139A1 (en)	2006-03-29	2007-11-08	The Regents Of The University Of California	Diaryl thiohydantoin compounds and their use in the treatment of hyperproliferative disorders
US8680291B2 (en) *	2007-10-26	2014-03-25	The Regents Of The University Of California	Diarylhydantoin compounds
US8450290B2 (en) *	2007-11-26	2013-05-28	Enzon Pharmaceuticals, Inc.	Methods for treating androgen receptor dependent disorders including cancers
US20110130296A1 (en)	2008-03-14	2011-06-02	The Regents Of The University Of California	Multi-gene classifiers and prognostic indicators for cancers
PL2297359T4 (pl)	2008-05-30	2014-07-31	Univ North Carolina Chapel Hill	Profile ekspresji genów do przewidywania skutków raka piersi
SG10201402628VA (en) *	2009-02-24	2014-10-30	Medivation Prostate Therapeutics Inc	Specific Diarylhydantoin And Diarylthiohydantoin Compounds
US8710086B2 (en)	2009-04-09	2014-04-29	Medivation Technologies, Inc.	Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof
US8507195B2 (en)	2009-08-20	2013-08-13	The Regents Of The University Of Colorado	MiRNAs dysregulated in triple-negative breast cancer
EP2485804A4 (en) *	2009-10-07	2015-07-29	Medivation Technologies Inc	SUBSTITUTED PHENYLCARBAMOYL ALKYLAMINOAREN COMPOUNDS AND N, N'-BIS-ARYL UREA COMPOUNDS
AU2012229123B2 (en)	2011-03-15	2017-02-02	British Columbia Cancer Agency Branch	Methods of treating breast cancer with anthracycline therapy
CN103997894B (zh) *	2011-07-29	2016-08-24	麦迪韦逊前列腺治疗股份有限公司	乳癌的治疗
EP2785873A4 (en)	2011-11-30	2015-11-11	Univ North Carolina	METHOD FOR THE TREATMENT OF BREAST CANCER WITH TAXAN THERAPY
EP2888594B1 (en)	2012-08-23	2018-08-15	The Regents of the University of Colorado, a body corporate	Method for determining breast cancer treatment
US9175291B2 (en)	2012-10-11	2015-11-03	Isis Pharmaceuticals Inc.	Modulation of androgen receptor expression
WO2014075067A1 (en)	2012-11-12	2014-05-15	Nanostring Technologies, Inc.	Methods to predict breast cancer outcome
US10679730B2 (en)	2013-05-28	2020-06-09	The University Of Chicago	Prognostic and predictive breast cancer signature
CA2970469A1 (en)	2014-12-12	2016-06-16	Amy Christian Peterson	Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer

2012
- 2012-07-27 CN CN201280048192.2A patent/CN103997894B/zh active Active
- 2012-07-27 HU HUE12846720A patent/HUE040524T2/hu unknown
- 2012-07-27 EP EP19187649.9A patent/EP3610731A1/en not_active Withdrawn
- 2012-07-27 CA CA2843417A patent/CA2843417C/en active Active
- 2012-07-27 BR BR112014002200A patent/BR112014002200A2/pt not_active Application Discontinuation
- 2012-07-27 DK DK12846720.6T patent/DK2739153T3/en active
- 2012-07-27 EA EA201400178A patent/EA028452B1/ru not_active IP Right Cessation
- 2012-07-27 EP EP20191500.6A patent/EP3791724A1/en not_active Withdrawn
- 2012-07-27 JP JP2014523048A patent/JP6158180B2/ja active Active
- 2012-07-27 EP EP18190012.7A patent/EP3430907A1/en not_active Withdrawn
- 2012-07-27 EP EP12846720.6A patent/EP2739153B1/en active Active
- 2012-07-27 PH PH1/2014/500248A patent/PH12014500248B1/en unknown
- 2012-07-27 SI SI201231453T patent/SI2739153T1/sl unknown
- 2012-07-27 US US14/236,036 patent/US9517229B2/en active Active
- 2012-07-27 ES ES12846720T patent/ES2696074T3/es active Active
- 2012-07-27 KR KR1020147005617A patent/KR101923250B1/ko active Active
- 2012-07-27 MX MX2014001218A patent/MX359664B/es active IP Right Grant
- 2012-07-27 PT PT12846720T patent/PT2739153T/pt unknown
- 2012-07-27 PL PL12846720T patent/PL2739153T3/pl unknown
- 2012-07-27 WO PCT/US2012/048471 patent/WO2013066440A1/en not_active Ceased
2016
- 2016-12-09 US US15/373,914 patent/US10111861B2/en active Active
2017
- 2017-03-31 JP JP2017072819A patent/JP2017141269A/ja active Pending
2018
- 2018-10-24 US US16/168,896 patent/US20190262315A1/en not_active Abandoned
- 2018-11-08 CY CY181101174T patent/CY1121038T1/el unknown
2020
- 2020-01-22 US US16/749,133 patent/US20210069154A1/en not_active Abandoned

Also Published As

Publication number	Publication date
MX2014001218A (es)	2014-08-22
PH12014500248B1 (en)	2018-08-31
BR112014002200A2 (pt)	2017-03-07
JP2017141269A (ja)	2017-08-17
CY1121038T1 (el)	2019-12-11
WO2013066440A9 (en)	2013-07-18
EP2739153B1 (en)	2018-08-22
US20210069154A1 (en)	2021-03-11
EP2739153A4 (en)	2015-03-11
EP2739153A1 (en)	2014-06-11
EA201400178A1 (ru)	2014-11-28
JP2014524934A (ja)	2014-09-25
PH12014500248A1 (en)	2014-03-17
HK1201413A1 (en)	2015-09-04
EA028452B1 (ru)	2017-11-30
HUE040524T2 (hu)	2019-03-28
ES2696074T3 (es)	2019-01-14
EP3430907A1 (en)	2019-01-23
US20190262315A1 (en)	2019-08-29
MX359664B (es)	2018-10-05
CN103997894B (zh)	2016-08-24
EP3791724A1 (en)	2021-03-17
CA2843417C (en)	2018-08-21
US10111861B2 (en)	2018-10-30
US9517229B2 (en)	2016-12-13
EP3610731A1 (en)	2020-02-19
CA2843417A1 (en)	2013-05-10
KR20140107174A (ko)	2014-09-04
CN103997894A (zh)	2014-08-20
KR101923250B1 (ko)	2018-11-28
PT2739153T (pt)	2018-11-28
US20170087132A1 (en)	2017-03-30
WO2013066440A1 (en)	2013-05-10
PL2739153T3 (pl)	2019-04-30
DK2739153T3 (en)	2018-12-03
US20140296312A1 (en)	2014-10-02
JP6158180B2 (ja)	2017-07-05
HK1198867A1 (en)	2015-06-19

Publication	Publication Date	Title
PH12014500248A1 (en)	2014-03-17	Treatment of breast cancer
GB2495841B (en)	2016-02-10	Phytocannabinoids for use in the treatment of breast cancer
IL232530A0 (en)	2014-06-30	Combined cancer treatment
EP2751267A4 (en)	2015-01-07	METHOD FOR THE TREATMENT OF BREAST CANCER
IL237558A0 (en)	2015-04-30	Methods for treating locally advanced breast cancer
EP2760452A4 (en)	2015-04-01	METHODS OF TREATING CANCER
IL232890A0 (en)	2014-07-31	Immunogenic therapy for cancer
SG10201508495VA (en)	2015-11-27	Combination treatment of cancer
IL228430A0 (en)	2013-12-31	Cancer treatment
EP2788378A4 (en)	2015-09-09	ASSOCIATION THERAPY FOR THE TREATMENT OF CANCER
EP2638397A4 (en)	2016-06-01	METHODS OF TREATING CANCER
EP2903644A4 (en)	2016-03-09	TREATMENT OF CANCER
GB201217892D0 (en)	2012-11-21	Treatment of cancer
SI2892925T1 (sl)	2020-11-30	Kombinacijsko zdravljenje raka
GB201412831D0 (en)	2014-09-03	Detection and treatment of breast cancer
GB201217890D0 (en)	2012-11-21	Treatment of cancer
IL237229A0 (en)	2015-04-30	Methods of treating cancer using lipoplatin
GB201121783D0 (en)	2012-02-01	Treatment of cancer
GB201121791D0 (en)	2012-02-01	Combination treatment of cancer
GB201200262D0 (en)	2012-02-22	Therapy of breast cancer
GB201208296D0 (en)	2012-06-20	Treatment of cancer
GB201017354D0 (en)	2010-11-24	Treatment of cancer
IL232266A0 (en)	2014-06-30	Cancer treatment methods
GB201222949D0 (en)	2013-01-30	Combination Treatment of Cancer
GB201222950D0 (en)	2013-01-30	Combination treatment of cancer